Skip to main content
. 2013 Sep 25;8:57–67. doi: 10.2147/CE.S35675

Core evidence clinical impact summary for sugammadex

Outcome measure Evidence Implications
Patient-oriented evidence
Reversal of neuromuscular block by rocuronium or vecuronium Multiple randomized clinical trials and comparison to antagonists Efficient reversor of neuromuscular block and superior to antagonists regarding efficacy
Recommended doses for profound, deep and moderate neuromuscular block (immediate reversal following 1.2 mg/kg rocuronium, PTC 1–2, TOF-C 2) Multiple randomized clinical trials Recommended doses are currently under postmarketing surveillance (Phase IV)
Doses for shallow neuromuscular block (TOF-C 4, TOF ratio 0.5) Single center randomized trials Further studies (including safety) pending
Disease-oriented evidence
Renal disease Multicenter parallel-group trial 2 mg/kg sugammadex is efficient in patients with renal failure (creatinine clearance <30 mL/min), however current recommendations are to use sugammadex only if creatinine clearance >30 mL/min
Obese patients Single center randomized trials (heterogeneous comparison groups) Doses according to ideal body weight +40% instead of actual body weight seems to be efficient for reversal
RSI Several randomized clinical trials Combination of rocuronium and sugammadex are an alternative to succinylcholine for RSI
Cesarian section Several case series Rocuronium and sugammadex might be a possible alternative to succinylcholine for RSI for patients undergoing a Cesarian section
Electroconvulsive therapy Single center trials (one randomized) Rocuronium followed by 8 mg/kg sugammadex after electroconvulsive therapy is completed seems to be an alternative to succinylcholine
Myasthenia gravis and muscular diseases Case reports Sugammadex seems to be efficient in such patients
Allergic/anaphylactic reaction to rocuronium Case reports and preclinical data Might be useful however standard treatment of anaphylaxis has priority
Economic evidence Limited data. Cost-effectiveness not proven.
No prospective randomized economic trials Economic benefits highly dependent on country, state or hospital reimbursement system as well as operation room logistics

Abbreviations: PTC, post tetanic count; TOF-C, train of four count; RSI, rapid sequence induction.